Arai Honoka, Maki Kazuhiro, Tadokoro Jiro, Handa Tomoyuki, Nakamura Yuko, Tsurumi Shigeharu, Sasaki Ko, Mitani Kinuko
Department of Hematology and Oncology, Dokkyo Medical University School of Medicine.
Rinsho Ketsueki. 2012 Jul;53(7):705-9.
We report a 69-year-old male with CD3-positive peripheral T-cell lymphoma, not otherwise specified (PTCL-nos). Interestingly, tumor cells slightly expressed CD20 as well. Southern analyses of the tumor cells showed rearrangement for only the T cell receptor gene but not the immunoglobulin genes. This patient achieved partial remission with a treatment regimen of THP-COP excluding prednisolone, but died of pneumonia. Although CD20-positive PTCL is rare, a review of the reported cases suggests that CD20-positive PTCL has a poor prognosis and that bone marrow infiltration of tumor cells results in a poorer prognosis in CD20-positive PTCL than in usual PTCL. By accumulating cases of this rare entity of lymphoma, we need to clarify the biological nature of the tumor cells and usefulness of rituximab combined with standard chemotherapy.
我们报告了一例69岁男性，患有未另行指定的CD3阳性外周T细胞淋巴瘤（PTCL-nos）。有趣的是，肿瘤细胞也轻微表达CD20。对肿瘤细胞的Southern分析显示仅T细胞受体基因发生重排，而免疫球蛋白基因未重排。该患者采用不含泼尼松龙的THP-COP治疗方案实现了部分缓解，但死于肺炎。尽管CD20阳性的PTCL很少见，但对已报道病例的回顾表明，CD20阳性的PTCL预后较差，并且与普通PTCL相比，肿瘤细胞的骨髓浸润会导致CD20阳性PTCL的预后更差。通过积累这种罕见淋巴瘤实体的病例，我们需要阐明肿瘤细胞的生物学特性以及利妥昔单抗联合标准化疗的有效性。
